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smaller than 1.0 cm; the stage was IA in 5
patients and IIIA in 1 patient. For the entire
16 patients with ground-glass opacities, the
stage was IA in 13, IB in 1, and IIIA in 2.
Our report, however, only examined those
patients who underwent surgical interven-
tion, so it does not represent a complete
description of all patients in our CT screen-
ing trial with ground-glass opacities. We
eagerly await continued reporting from the
radiology literature about the entire spec-
trum of patients found to have ground-glass
opacity on a screening CT.
The question regarding computer-aided
diagnosis for enlargement of small nodules is
provocative. Three-dimensional computer-
aided diagnosis is clearly superior to 2-
dimensional human measurement. This
would be the preferred technique only when
it can be smoothly automated for efficient use
in day-to-day practice.1
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Why clopidogrel failed to inhibit
platelet function early after coronary
artery bypass surgery: To load or not
to load, and is it a question of
resistance?
To the Editor:
Antiplatelet therapy remains a topic of
much-deserved attention and debate. We
read with interest the recent article by Lim
and associates1 in which they found that
clopidogrel after coronary artery bypass
grafting failed to inhibit platelet function,
on the basis of the percentage platelet ag-
gregation on day 5. Patients were random-
ized to receive 100 or 325 mg of aspirin
daily or 75 mg of clopidogrel daily for 5
days after coronary artery bypass grafting.
It is not clear whether patients in the clo-
pidogrel arm received a loading dose be-
fore the daily maintenance dose. Several
similar studies assessing platelet inhibition,
albeit in the context of percutaneous coro-
nary intervention, have demonstrated the
importance of appropriate loading of 300 to
600 mg if steady-state levels of platelet
aggregation are to be achieved within the
first 24 hours.2-4 Daily maintenance dosing
with 75 mg of clopidogrel without preload-
ing, as in this study, has been shown to
result in steady-state levels of platelet in-
hibition only after 3 to 7 days.5
The second observation with regard to
this study is that the investigators did not
state whether a baseline pretreatment sam-
ple was taken before surgery or before ad-
ministration of the antiplatelet therapy.
Whether this would have added much to
the final analysis remains unclear, but evi-
dence, again drawn from studies in the
percutaneous coronary intervention setting,
have suggested pretreatment platelet reac-
tivity to be an important determinant of
posttreatment reactivity.6
The final comment is the most elusive,
namely, the issue of “clopidogrel resis-
tance.” Although it was not directly men-
tioned by the authors, we can assume that it
was alluded to in their discussion. It is
likely that a correlation exists between a
laboratory measure of clinical clopidogrel
nonresponsiveness and the clinical out-
come. However, until such time as there is
greater understanding of the likely mecha-
nisms of clopidogrel responsiveness and the
individual heterogeneity that is apparent, can
we totally dismiss the efficacy of clopidogrel
in the early postoperative period?
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Reply to the Editor:
In our reply to Raja, we have addressed a
similar query with regard to the dosing
regimen of clopidogrel. It is vitally impor-
tant to appreciate that the study in which
Hunt and associates quote the time to the
onset of the effects of clopidogrel (4 to 7
days) is from a sample of healthy subjects.1
Nonrandomized studies after coronary ar-
tery bypass surgery suggest that it takes 9
to 28 days.2 Our results are consistent with
the latter.
In our article, you will note that we
reported all measurements as the percent-
age change compared with baseline.3 The
baseline sample was taken on the day be-
fore surgery.
We respectfully disagree with the final
comment of Hunt. A previous observa-
tional study and our randomized data are
consistent regarding the inefficacy of clo-
pidogrel early after coronary surgery as-
sessed on aggregometry. At present, we are
unaware of any evidence to the contrary;
therefore, the onus should be to prove that
an effect exists before prescribing clopi-
dogrel (as the sole antiplatelet in this time
frame), rather than subjecting patients to
the possibility of ineffective treatment
while awaiting a “greater understanding of
the likely mechanisms of clopidogrel re-
sponsiveness.”
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